These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 20465658)

  • 21. Secondary osteoporosis: underlying disease and the risk for glucocorticoid-induced osteoporosis.
    Boling EP
    Clin Ther; 2004 Jan; 26(1):1-14. PubMed ID: 14996513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comprehensive review of the adverse effects of systemic corticosteroids.
    Poetker DM; Reh DD
    Otolaryngol Clin North Am; 2010 Aug; 43(4):753-68. PubMed ID: 20599080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Undesired effects of cimetidine: review of the literature].
    Del Favero A; Morelli A; Narducci F
    Clin Ter; 1981 Jan; 96(1):81-91. PubMed ID: 7016411
    [No Abstract]   [Full Text] [Related]  

  • 24. Cross-sectional study of bisphosphonate use in dermatology patients receiving long-term oral corticosteroid therapy.
    Liu RH; Albrecht J; Werth VP
    Arch Dermatol; 2006 Jan; 142(1):37-41. PubMed ID: 16415384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral glucocorticoids and their complications. A review.
    Gallant C; Kenny P
    J Am Acad Dermatol; 1986 Feb; 14(2 Pt 1):161-77. PubMed ID: 3512634
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
    Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
    Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Adverse effects of psychotropic agents].
    Owashi T; Kamijima K
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():247-53. PubMed ID: 18074545
    [No Abstract]   [Full Text] [Related]  

  • 28. Glucocorticoid-induced osteoporosis.
    Saag KG
    Endocrinol Metab Clin North Am; 2003 Mar; 32(1):135-57, vii. PubMed ID: 12699296
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Nonsteroidal anti-inflammatory drugs and glucocorticoids for treatment of connective tissue diseases].
    Yamamoto T; Kawai S
    Nihon Rinsho; 2009 Mar; 67(3):576-81. PubMed ID: 19280935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Assessment of the treatment of glucocorticoid-induced osteoporosis].
    Asano S; Suzuki A
    Clin Calcium; 2013 Mar; 23(3):401-8. PubMed ID: 23445894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucocorticoid-induced osteoporosis: pathogenesis, diagnosis, and management.
    McIlwain HH
    Prev Med; 2003 Feb; 36(2):243-9. PubMed ID: 12591000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis.
    Lekamwasam S; Adachi JD; Agnusdei D; Bilezikian J; Boonen S; Borgström F; Cooper C; Perez AD; Eastell R; Hofbauer LC; Kanis JA; Langdahl BL; Lesnyak O; Lorenc R; McCloskey E; Messina OD; Napoli N; Obermayer-Pietsch B; Ralston SH; Sambrook PN; Silverman S; Sosa M; Stepan J; Suppan G; Wahl DA; Compston JE;
    Arch Osteoporos; 2012; 7():25-30. PubMed ID: 23225278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on glucocorticoid-induced osteoporosis.
    Maricic M
    Rheum Dis Clin North Am; 2011 Aug; 37(3):415-31, vi. PubMed ID: 22023900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Update on the dermatologic use of systemic glucocorticosteroids.
    Jackson S; Gilchrist H; Nesbitt LT
    Dermatol Ther; 2007; 20(4):187-205. PubMed ID: 17970885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Current antalgic anti-inflammatory drugs].
    Henrard JC
    Presse Med (1893); 1970 Jun; 78(31):1419-23. PubMed ID: 5428230
    [No Abstract]   [Full Text] [Related]  

  • 36. Glucocorticoid-induced osteoporosis: treatment options and guidelines.
    Maricic M
    Curr Osteoporos Rep; 2005 Mar; 3(1):25-9. PubMed ID: 16036098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population-based trends in osteoporosis management after new initiations of long-term systemic glucocorticoids (1998-2008).
    Majumdar SR; Lix LM; Yogendran M; Morin SN; Metge CJ; Leslie WD
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1236-42. PubMed ID: 22298803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucocorticoid-induced osteoporosis: prevention and treatment.
    Werth VP
    Rev Rhum Engl Ed; 1997 Jun; 64(6 Suppl):84S-88S. PubMed ID: 9273946
    [No Abstract]   [Full Text] [Related]  

  • 39. Adverse effects of corticosteroids: II. Systemic.
    Davis GF
    Clin Dermatol; 1986; 4(1):161-9. PubMed ID: 2978681
    [No Abstract]   [Full Text] [Related]  

  • 40. [Secondary osteoporosis UPDATE. Clinical significance of glucocorticoid-induced osteoporosis].
    Suzuki Y; Sato S
    Clin Calcium; 2010 May; 20(5):645-53. PubMed ID: 20445275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.